8USM

FmlH Lectin Domain UTI89 - AM4085

Summary for 8USM

• Entry DOI: 10.2210/pdb8usm/pdb
• Descriptor: Fimbrial protein (Fragment), 4'-fluoro-6-(trifluoromethyl)[1,1'-biphenyl]-2-yl 2-acetamido-2-deoxy-beta-D-galactopyranoside (3 entities in total)
• Functional Keywords: adhesin inhibitor, cell adhesion
• Biological source: Escherichia coli
• Total number of polymer chains: 2
• Total formula weight: 36758.95

Authors

Tamadonfar, K.O.,Pinkner, J.P.,Maddirala, A.R.,Janetka, J.W.,Hultgren, S.J. (deposition date: 2023-10-27, release date: 2024-02-14, Last modification date: 2024-11-06)

Primary citation

Maddirala, A.R.,Tamadonfar, K.,Pinkner, J.S.,Sanick, D.,Hultgren, S.J.,Janetka, J.W.
Discovery of Orally Bioavailable FmlH Lectin Antagonists as Treatment for Urinary Tract Infections.
J.Med.Chem., 67:3668-3678, 2024

PubMed Abstract: FmlH, a bacterial adhesin of uropathogenic (UPEC), has been shown to provide a fitness advantage in colonizing the bladder during chronic urinary tract infections (UTIs). Previously reported -biphenyl glycosides based on βGal and βGalNAc have excellent binding affinity to FmlH and potently block binding to its natural carbohydrate receptor, but they lack oral bioavailability. In this paper, we outline studies where we have optimized compounds for improved pharmacokinetics, leading to the discovery of novel analogues with good oral bioavailability. We synthesized galactosides with the anomeric O-linker replaced with more stable S- and C-linked linkers. We also investigated modifications to the GalNAc sugar and modifications to the biphenyl aglycone. We identified GalNAc with an IC of 0.19 μM against FmlH and 53% oral bioavailability in mice. We also obtained a FimlH-bound X-ray structure of lead compound (AM4085) which has potential as a new antivirulence therapeutic for UTIs.

PubMed: 38308631
DOI: 10.1021/acs.jmedchem.3c02128

Experimental method

X-RAY DIFFRACTION (1.63 Å)